Pulmonx Corporation
LUNG
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and preā¦ read more
Healthcare
Medical Devices
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.63
Price+1.24%
$0.02
1Y
Price
Market Cap
$68.847m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-59.4%
EBITDA Margin-64.9%
Net Profit Margin-38.4%
Free Cash Flow Margin-59.4%
EBITDA Margin-64.9%
Net Profit Margin-38.4%
Free Cash Flow MarginRevenue
$87.442m
+9.4%
1y CAGR+19.8%
3y CAGR+17.6%
5y CAGREarnings
-$48.116m
-0.6%
1y CAGR+1.1%
3y CAGR-4.4%
5y CAGREPS
-$1.15
+2.1%
1y CAGR+3.8%
3y CAGR-1.6%
5y CAGRBook Value
$39.196m
$114.732m
Assets$75.536m
Liabilities$56.211m
DebtDebt to Assets
49.0%
-1x
Debt to EBITDAFree Cash Flow
-$25.454m
+1.1%
1y CAGR+10.9%
3y CAGR+7.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company